+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market 2019-2023

  • PDF Icon


  • 108 Pages
  • October 2018
  • Region: Global
  • TechNavio
  • ID: 4662740
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Idiopathic Thrombocytopenic Purpura

Platelets are the blood cells that help to stop bleeding. Idiopathic thrombocytopenic purpura (ITP) is caused due to abnormal decrease in the platelet count. This disease is also called immune thrombocytopenic purpura.

The analysts forecast the Global Idiopathic Thrombocytopenic Purpura Therapeutics Market to grow at a CAGR of 5.41% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the idiopathic thrombocytopenic purpura therapeutics market. To calculate the market size, the report considers the revenue generated from the application of idiopathic thrombocytopenic purpura therapeutics across the globe.

The market is divided into the following segments based on geography:
  • Americas

  • APAC

  • EMEA

The report, idiopathic thrombocytopenic purpura therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen

  • Bristol-Myers Squibb

  • Eisai

  • Merck Sharp & Dohme

  • Novartis

Market drivers
  • Increasing second- and third-line therapies.

  • For a full, detailed list, view the full report

Market challenges
  • Side effects of approved treatment

  • For a full, detailed list, view the full report

Market trends
  • Development of combination therapy for ITP

  • For a full, detailed list, view the full report

Key questions answered in this report
  • What will the market size be in 2023 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the Key vendors?

  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

Table of Contents

  • Market ecosystem

  • Market characteristics

  • Market segmentation analysis

  • Market definition

  • Market sizing 2018

  • Market size and forecast 2018-2023

  • Bargaining power of buyers

  • Bargaining power of suppliers

  • Threat of new entrants

  • Threat of substitutes

  • Threat of rivalry

  • Market condition

  • Market segmentation by product

  • Comparison by product

  • Biologics - Market size and forecast 2018-2023

  • Small molecules - Market size and forecast 2018-2023

  • Market opportunity by product

  • Geographic segmentation

  • Geographic comparison

  • Americas - Market size and forecast 2018-2023

  • EMEA - Market size and forecast 2018-2023

  • APAC - Market size and forecast 2018-2023

  • Key leading countries

  • Market opportunity

  • Market drivers

  • Market challenges

  • Overview

  • Landscape disruption

  • Vendors covered

  • Vendor classification

  • Market positioning of vendors

  • Amgen

  • Bristol-Myers Squibb

  • Eisai

  • Merck Sharp & Dohme

  • Novartis

  • Research methodology

  • List of abbreviations

PART 15: About the Author
List of Exhibits
Exhibit 01: Global rare disease market
Exhibit 02: Segments of global rare disease market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 21: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Decision framework
Exhibit 39: Molecules in late-stage development in 2017-2018
Exhibit 40: Recent approvals
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Amgen - Vendor overview
Exhibit 48: Amgen - Business segments
Exhibit 49: Amgen - Organizational developments
Exhibit 50: Amgen - Segment focus
Exhibit 52: Amgen - Key offerings
Exhibit 53: Amgen - Key customers
Exhibit 54: Bristol-Myers Squibb - Vendor overview
Exhibit 55: Bristol-Myers Squibb - Business segments
Exhibit 56: Bristol-Myers Squibb - Organizational developments
Exhibit 57: Bristol-Myers Squibb - Segment focus
Exhibit 59: Bristol-Myers Squibb - Key offerings
Exhibit 60: Bristol-Myers Squibb - Key customers
Exhibit 61: Eisai - Vendor overview
Exhibit 62: Eisai - Business segments
Exhibit 63: Eisai - Organizational developments
Exhibit 64: Eisai - Segment focus
Exhibit 66: Eisai - Key offerings
Exhibit 67: Eisai - Key customers
Exhibit 68: Merck Sharp & Dohme - Vendor overview
Exhibit 69: Merck Sharp & Dohme - Business segments
Exhibit 70: Merck Sharp & Dohme - Organizational developments
Exhibit 71: Merck Sharp & Dohme - Segment focus
Exhibit 73: Merck Sharp & Dohme - Key offerings
Exhibit 74: Merck Sharp & Dohme - Key customers
Exhibit 75: Novartis - Vendor overview
Exhibit 76: Novartis - Business segments
Exhibit 77: Novartis - Organizational developments
Exhibit 78: Novartis - Segment focus0
Exhibit 80: Novartis - Key offerings0
Exhibit 81: Novartis - Key customers1
Exhibit 82: Validation techniques employed for market sizing4
Exhibit 83: List of abbreviations6

Executive Summary

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market 2019-2023

The author of the report recognizes the following companies as the key players in the global idiopathic thrombocytopenic purpura therapeutics market: Amgen, Bristol-Myers Squibb, Eisai, Merck Sharp & Dohme, and Novartis.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the development of combination therapy for ITP. The ITP market is coming up with many combination therapies for the treatment of the disease with many positive outcomes.”

According to the report, one driver influencing this market is the increasing second- and third-line therapies. The global ITP therapeutics market is witnessing an increase in the inflow of second and third-line therapies to meet the unmet needs of ITP.

Further, the report states that one challenge affecting this market is the side effects of approved treatment. Many approved therapeutics cause serious side effects which is a key challenge in the global ITP therapeutics market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen

  • Bristol-Myers Squibb

  • Eisai

  • Merck Sharp & Dohme

  • Novartis